Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in patients with HCV/HIV co-infection with its investigational drug faldaprevir.

Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups. Further, 80% of all patients were eligible for randomization to a shortened duration of treatment (24 versus 48 weeks) because they achieved protocol-defined early treatment success (ETS) and 86% of these patients achieved SVR12. STARTVerso 4 is a Phase III trial that enrolled 308 hepatitis C (HCV) treatment-naive or experienced patients with HCV/HIV co-infectionand evaluated the efficacy and safety of the investigational compound faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).